

Product datasheet for **TL310430**

PIK3C2G Human shRNA Plasmid Kit (Locus ID 5288)

Product data:

Product Type:	shRNA Plasmids
Product Name:	PIK3C2G Human shRNA Plasmid Kit (Locus ID 5288)
Locus ID:	5288
Synonyms:	PI3K-C2-gamma; PI3K-C2GAMMA
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	PIK3C2G - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 5288). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	NM_001288772 , NM_001288774 , NM_004570 , NM_004570.2 , NM_004570.3 , NM_004570.4 , NM_004570.5 , NM_001288774.1 , NM_001288772.1 , BC130277 , BC144133 , BC144134 , NM_001288772.2
UniProt ID:	O75747
Summary:	The protein encoded by this gene belongs to the phosphoinositide 3-kinase (PI3K) family. PI3-kinases play roles in signaling pathways involved in cell proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking. This protein contains a lipid kinase catalytic domain as well as a C-terminal C2 domain, a characteristic of class II PI3-kinases. C2 domains act as calcium-dependent phospholipid binding motifs that mediate translocation of proteins to membranes, and may also mediate protein-protein interactions. This gene may play a role in several diseases, including type II diabetes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2014]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).